Drug Type Small molecule drug |
Synonyms (25R)-5beta-Spirostan-3beta-ol, (25R)-Spirostan-3beta-ol, Isosarsapogenin + [7] |
Target |
Action agonists |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), GDNFR agonists(Glial cell line-derived neurotrophic factor receptors agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H44O3 |
InChIKeyGMBQZIIUCVWOCD-UQHLGXRBSA-N |
CAS Registry126-18-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sarsasapogenin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Young onset Parkinson disease | Phase 2 | United States | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Canada | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Czechia | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | France | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Germany | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Hungary | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Poland | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Romania | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | Serbia | 01 Nov 2010 | |
Young onset Parkinson disease | Phase 2 | United Kingdom | 01 Nov 2010 |
Not Applicable | - | iyhkekipre(chtfcnqlks) = tcbqkiplxw fsjbqawvjn (hqtgzwjidn ) View more | - | 01 Oct 2018 | |||
fxtfrwvbty(lbxfkhinnx) = mfcnlesxwz pgcgrjvhgg (mqxvslxfka ) |